United States: FDA Issues Draft Memorandum Of Understanding For 503A Drug Compounding

Included in the flurry of guidance documents recently issued by the FDA concerning human drug compounding is a long-awaited document of great importance to mail-order pharmacy compounders and entities that rely on interstate distribution of prescription compounded drugs—a Draft Memorandum of Understanding (MOU) between the FDA and each of the 50 states. As previously discussed, this MOU has been the subject of controversy since section 503A of the FFDCA was first enacted in 1997 and this controversy again took center stage following enactment of the DQSA in 2013.

The controversy arises from a key provision of Section 503A of the FFDCA that limits the amount of compounded prescriptions a pharmacy is permitted to ship across state lines. Specifically, unless the pharmacy is located in a state that has entered into an MOU with the FDA, Section 503A of the FFDCA prohibits a pharmacy from dispensing or distributing more than five percent of the pharmacy's total prescription orders to patients outside of the state in which the pharmacy is located. This is often referred to as the "5% Rule." More specifically, Section 503A states that drugs compounded by a traditional compounding pharmacy only qualify for exemptions from adequate directions for use, new drug application requirements/approval and cGMP requirements if, among other things, one of the following conditions is met:

  • The drugs are compounded in a state that has entered into an MOU with the FDA that addresses the distribution of "inordinate amounts" of compounded drug products interstate and provides for appropriate investigation by a state agency of complaints relating to compounded drug products distributed outside such state; or
  • If the drugs are compounded in a state that has not entered into an MOU, the drugs are compounded in quantities that do not exceed five percent of the total prescription drug orders dispensed or distributed by the pharmacy or physician.

As originally enacted, Section 503A required the FDA to consult with the National Association of Boards of Pharmacy (NABP) to develop a standard MOU for use by the states in lieu of 50 separate MOUs. In January 1999, the FDA, in consultation with the NABP, published a draft MOU in the Federal Register (1999 MOU) that generated over 6,000 comments. However, shortly after publication of the 1999 MOU, the constitutionality of Section 503A was called into question and the FDA never finalized the 1999 MOU.

The DQSA settled the constitutional uncertainty that had delayed finalization of the 1999 MOU, and in Draft Guidance issued pursuant to the DQSA's modification to Section 503A, the FDA indicated that the FDA intended to publish a new draft of the MOU. Interestingly, the FDA also addressed the MOU and the 5% Rule at the Inter-Governmental Working Meeting on Pharmacy Compounding, during which Dr. Jane Axelrad, Associate Director for Policy at the FDA's Center for Drug Evaluation and Research and a key player in compounding pharmacy regulation, prepared a presentation specifically addressing the topic and issues that had been left unsettled in 1999, such as how the FDA should define "inordinate amounts" in the MOU and whether the restrictions on interstate distribution should account for contiguous states. This meeting was with representatives from various state boards of pharmacy and the NABP. The recently released Draft MOU has provided some clarity on some of these issues while remaining silent on others.

Under the Draft MOU, a pharmacist, pharmacy or physician distributes an "inordinate amount" of compounded human drug products interstate if the number of units of compounded human drug products distributed interstate during any calendar month is equal to or greater than 30 percent or more of its total number of compounded and non-compounded drug products—up from the 20 percent ratio included in the 1999 MOU. The 30 percent amount does not include prescriptions dispensed to a patient or his agent who then carries the compounded drug across state lines. Noticeably absent here is any accommodation for the distribution of compounded human drugs among contiguous states. Additionally, a note under the definition of the term "distribution" in the appendix of the Draft MOU states that the MOU "will not alter" Section 503A requirements that a compounder obtain a prescription for an individually identified patient in order to qualify for exemptions under the FFDCA. This provision seems somewhat at odds with Section 503A provisions allowing drug compounding in limited quantities before the receipt of a valid prescription in certain circumstances.

The Draft MOU provides that a state agency will conduct an "appropriate investigation" of complaints concerning compounded drugs distributed interstate and spells out six requirements for a state to investigate complaints about compounded drugs that were distributed across state lines:

  1. The "appropriate agencies" of the state will investigate complaints received relating to human drug products compounded by a pharmacist, pharmacy or physician located within the state and distributed outside the state. The Draft MOU allows for the pharmacy board or "other appropriate state agency" and the state medical licensing board or other state agency to cooperate in investigating complaints involving overlapping jurisdiction.
  2. Complaints to be investigated will include reports received by the state concerning adverse drug experiences or product quality issues that, if left uncorrected, could lead to potential public health risks or safety concerns.
  3. Any investigation conducted by the state must include (1) determining whether there is a public health risk or safety concern associated with the compounded product, and (2) confirming that any risk or safety concern is sufficiently kept in check so as to eliminate any ongoing risk to the public.
  4. If the state's investigation of the complaint concludes the complaint is valid, the state will take "appropriate action" to ensure that the relevant person or entity that compounded the drug at issue "determines the root cause of the problem ... and undertakes sufficient corrective action" to eliminate any public health risk, including the risk of future complaints. The Draft MOU does not provide additional detail or guidance as to what constitutes "appropriate action" or "sufficient corrective action."
  5. The state will notify the FDA within 72 hours of receiving any such complaint that involves a public health risk or immediate safety concern. The notification must include the state's initial assessment of the complaint's validity and a description of any actions the state has taken or plans to take to address the complaint.
  6. The state will maintain records of the complaint, the investigation and any response or action taken. The state must maintain records for at least three years.

The Draft MOU also requires the state to take certain actions in connection with the distribution of inordinate amounts of compounded drugs:

  • The state agrees to review compounding records during inspections to determine whether the compounder is distributing inordinate amounts of compounded drugs interstate.
  • The state will notify the FDA within seven days of identifying a compounder that has distributed inordinate amounts of compounded drugs interstate.
  • The state "will take action" regarding any compounder that distributes an inordinate amount interstate. Such action can include a warning letter, enforcement action, suspension, revocation of a license or any other action consistent with state law. The Draft MOU also empowers the FDA to take action.

The Draft MOU mandates that when a state submits information to the FDA concerning complaints or distribution of inordinate amounts of compounded drugs, certain minimum information be included:

  • The complainant's name and contact information, in the case of a complaint;
  • The name and address of the pharmacist/pharmacy/physician that is the subject of the complaint or distribution of inordinate amounts;
  • A description of the complaint, or of the evidence indicating that the compounder distributed inordinate amounts, including a description of any compounded drug that is the subject of the complaint or distribution;
  • The state's initial assessment of the validity of the complaint; and
  • A description and the date of any actions the state has taken to address the complaint or the distribution of inordinate amounts of compounded drugs.

The Draft MOU also provides that the state and the FDA may need to execute additional agreements or to commission certain officials before the FDA can share information that is protected from public disclosure. Such agreement or commissioning terms would govern sharing certain kinds of information:

  • Confidential commercial information that would be protected from public disclosure under Exemption 4 of the Freedom of Information Act (FOIA);
  • Personal privacy information that would be protected from disclosure under Exemption 6 or 7(C) of FOIA; or
  • Information that is otherwise protected from public disclosure from other federal statutes and regulations.

The Draft MOU provides that the state and the FDA recognize that each retains its statutory and regulatory authority. It also specifies that it does not restrict either the state or the FDA (or any other federal agency) from taking appropriate enforcement action to ensure compliance with applicable statutes and regulations. Under the terms of the Draft MOU, it will continue until terminated by either party and the FDA can terminate if the state does not adhere to the MOU.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions